

Format for ANSWERING REVIEWERS



April 22, 2014

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 9912-review.doc).

Title:

MicroRNAs: promising chemoresistance biomarkers in gastric cancer with diagnostic and therapeutic potential

Author:

Christiane Borchardt, Joerg Haier, Richard Hummel, Kirsten Lindner

Name of Journal:

World Journal of Gastroenterology

ESPS Manuscript NO: 9912

Comment: All changes in the manuscript that refer to reviewer's comments are highlighted in yellow.

The manuscript has been improved according to the suggestions of reviewers:

1 Format has been updated

2 Revision has been made according to the suggestions of the reviewer (see below)

3 References and typesetting were corrected

Reviewer 1:

This review manuscript contains information regarding the applicability of miRNAs as biomarkers in prediction of sensitivity towards different chemotherapeutics, as well as modulators of sensitivity and resistance towards chemotherapy in gastric cancer. The current information, although limited as the authors also mention, is of high interest and well presented in the manuscript, so it can be accepted for publication after the following corrections:

Page 2, Abstract: The terms “microRNA” and “miRNA” must be used in lines 8 and 9.

We adjusted the manuscript accordingly.

Page 3, line 17: ... water soluble

We adjusted the manuscript accordingly.

Page 4, line 5: messenger RNA

We adjusted the manuscript accordingly.

Page 4, line 10: miRNA

We adjusted the manuscript accordingly.

Page 4, line 23: “from a” is written twice

We revised the manuscript accordingly.

Page 6, line 13: use “are” instead of “is”

We adjusted the manuscript accordingly.

Page 6, line 21: add the right parenthesis after the number of ref. 58

We adjusted the manuscript accordingly.

Page 8, line 1 (title): miRNA

We adjusted the manuscript accordingly.

Page 8, line 15: (table 1).

We adjusted the manuscript accordingly.

Page 11, conclusion: the sentence “Based on the fact that miRNAs are on the one hand accessible and detectable in different tissue types including blood samples with great stability, and play on the other hand an important role in the development and regulation of multidrug resistance, these molecules seem to have great potential as new biomarkers for diagnostic and therapeutic approaches.” should be reorganised to “Based on the fact that miRNAs play an important role in the development and regulation of multidrug resistance, and in addition are accessible and detectable in different tissue types including blood samples with great stability, these molecules seem to have great potential as new biomarkers for diagnostic and therapeutic approaches.”

We thank the reviewer for this suggestion, and adjusted the manuscript accordingly.

Pages 24 and 27, legend of Fig. 1: Add a reference for DianaPath

We adjusted the manuscript accordingly.

Page 27, Figure 1: miRNAs up- or down-regulation in gastric cancer should be indicated in the figure.

We thank the reviewer for this suggestion, and adjusted the manuscript accordingly.

Reviewer 2:

This manuscript concerns a concise review on the use of miRNAs as biomarker and/or therapeutic tool in gastric cancer. Despite being an interesting topic I would have liked to see a more critical approach of the current literature and a section on hurdles that need to be taken before wide-spread application of miRNA biomarkers / therapeutics in the clinic.

1. Please include a section on future prospects listing the hurdles that need to be taken before miRNAs can be safely employed in the clinic. For example larger prospective clinical studies are necessary that systematically analyze miRNA expression both in serum and tumor tissue in relation to the response to defined chemotherapy regimens. Alternatively one may want to perform studies on animal models of gastric cancer before going to the clinic. The use of miRNA therapeutics comes with its own set of difficulties, what is the current state-of-affairs and what are the specific difficulties?

We thank the reviewer for this suggestion, and included a brief section to the manuscript highlighting the hurdles that have to be taken before a potential clinical use of miRNAs as diagnostic or therapeutic markers.

The distinction between diagnostic and therapeutic miRNAs is somewhat artificial. Please define exactly when a miRNA is of diagnostic use and when it does have therapeutic value. Are there any specific characteristics that need to be taken into account when dealing with gastric cancers?

We thank the reviewer for this comment. We added a section to the beginning of the paragraph “miRNAs and multidrug resistance in gastric cancer”, page 9, that highlights why we chose to focus on diagnostic and therapeutic biomarkers, and what specific characteristics are needed for these biomarkers. There are no specific characteristics that need to be taken into account when dealing with gastric cancer.

2. Figure 1 – It is unclear to me how this figure was generated and how it should be read. For example in the circle labelled “Jak-STAT signaling pathway” I notice cyclin D1, a cell cycle protein as well as two proteins involved in apoptosis Bcl-2 and Bcl-XL what is the link to the Jak-STAT pathway? Similarly, the circle MAPK signaling pathway is unclear. Please carefully check the figure and clearly describe how the figure was made.

We thank the reviewer for this comment. The pathway presentation in figure 1 has been revised. The figure was made using modified data from DIANA miRPath v2.0 (<http://diana.cslab.ece.ntua.gr/?sec=home>). This information has been added to the citation of the figure 1.

3. Page 6, line 24, page 7 line 1 – “In addition, several anti-cancer-drugs.....resistance via miRNAs” Please note in this respect that the regulation of known cancer related genes by miRNAs is much more frequently reported simply because these genes are well studied. In addition not all miRNAs show similar sensitivity phenotypes in different cancer types.

We thank the reviewer for this comment and addressed these limitations.

1. Page 3, line 9 – Please give appropriate references to MAGIC and ACCORD trials.

We adjusted the manuscript accordingly.

2. Page 3, line 13 – What exactly do the authors mean by “somewhat” resistant. Omit somewhat.

We adjusted the manuscript accordingly.

3. Page 3, line 22-23 – Use correct gene nomenclature for P-gp, ABCB1 and for breast cancer resistance protein, ABCG2.

We thank the reviewer for this comment and adjusted the manuscript accordingly.

4. Page 4, line 7 – So far, more over 2500 human should be: “So far, over 2500 human.....” Throughout the manuscript there are more small typographical /grammatical errors, please proofread carefully for these mistakes.

We adjusted the manuscript accordingly, and proofread the entire manuscript carefully.

5. Page 4, line 9 – As for most miRNAs it is not shown that they are truly able to target hundreds of mRNA, I recommend to rephrase this sentence clearly stating that “... each single miRNA can potentially target up to hundreds of mRNAs”.

We adjusted the manuscript accordingly.

6. Page 5, heading – omit the word “promising” from the heading.

We eliminated the word “promising” from the heading as requested.

7. Page 5, line 11 – What do the authors mean with “present a certain stability....” One wants biomarkers to be stably present , refractory to degradation, in the clinical samples in order to obtain reliable data. Please rephrase the text.

We thank the reviewer for this objection, and rephrased the text for a more precise statement.

8. Page 8 – please indicate that Adriamycin is in fact doxorubicin

We adjusted the manuscript accordingly and replaced the trade name “Adriamycin” by “doxorubicin” throughout the entire manuscript.

9. Page 9, line 6-18 – When describing studies involving patients / clinical samples it is important to mention the number of patients/ biopsies studied. In fact these are the more interesting studies as they entail direct measurements on patient samples and may be more “predictive” than studies involving cell lines.

We thank the reviewer for this suggestion, and added details about the sample sizes of the respective studies to this section.

10. Page 10, line 3 and line 5 – Please refer to Yang et al and Zhao et al by a reference number at the end of the sentence.

We adjusted the manuscript accordingly.

11. Page 16 – Reference 35, “Cucc Opin Pharmacol” should be “Curr Opin Pharmacol”

We adjusted the manuscript accordingly.

12. Page 19 – Reference 60, Zhao JP et al is not correct. This paper deals with miRNA expression in a tree namely *Populus trichocarpa*. Please correct!

We apologize for this mistake and corrected the respective reference.

13. Page 20 – page numbers and journal abbreviation in reference 63, Akao, Y et al

We adjusted the manuscript accordingly.

Reviewer 3:

This article entitled “MircroRMAs: promising biomarkers for chemoresistance in gastric cancer with diagnostic and therapeutic potential” by Borchardt et al shows an extensive and thorough review on Mi-RNAs so far reported up to present time. It is highly educational paper and the authors are commended.

While describing more than 20 miRNAs, authors can make a more succinct summary by putting informations in two groups than describing every individual miRNA; an example, on pages 8 through 10, when miRNAs are described as diagnostic and therapeutic potential. There are two groups of miRNAs, one group that downregulated and the other upregulated. While the authors summarized in tables 1 and 2, it is important to describe these MiRNAs in the text but in a simplified way. By this way, it would be far easier for the readers to follow the story.

We thank the reviewer for this suggestion, and structured the section “miRNAs as promising biomarkers for chemoresistance in gastric cancer with diagnostic potential” (page 9,10) and “MiRNAs as promising biomarkers for chemoresistance in gastric cancer with therapeutic potential” (page 11) depending on miRNA up- or downregulation.

**For references in serial numbers, only the first and the last
Number of references may be listed.**

We adjusted the manuscript accordingly.

In tables, if abbreviations (Target) are written out below the table, it would be easier for the readers.

We adjusted the manuscript accordingly

Thank you again for publishing our manuscript in the *World Journal of Gastroenterology*.

Sincerely yours,

Dr. med. K. Lindner
Dept. of General and Visceral Surgery
Muenster University Hospital
Waldeyerstr. 1, 48149 Muenster, Germany
Phone: +49 251 8356301
Fax: +49 251 8352400
Email: kirsten.lindner@ukmuenster.de